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Objective: Global incidence of contrast-induced nephrop-
athy (CIN) is 2–5%, but a recent Kenyan study highlighted
a local incidence of 12–14% without offering an explana-
tion for the higher incidence. This study proposes that
inflammatory states confer a higher relative risk for
development of CIN. Our objective was to determine
the risk of developing CIN given the presence of an
inflammatory state in patients in Kenya.
Methods: Prospective cohort study of patients under-
going a contrast-enhanced CT (CECT) scan in a private
university teaching hospital in Kenya and having no
known risk factors for CIN. 423 patients were recruited
and grouped into those without inflammation (unexposed)
having serum C-reactive protein (CRP) levels #5mgdl21
and those with evidence of inflammation having CRP
levels .5mgdl21. Serum creatinine (SCr) was measured
before the CECT and 48h following the CECT with CIN
diagnosed by an increase of .25% in the SCr from the
baseline. Relative risk was determined and multiple
logistic regression analysis performed on biophysical
variables and contrast volume to assess their effect on
development of CIN.
Results: Patients with high CRP levels had a relative risk
of developing CIN of 2.16 compared with those with
normal levels of CRP (p50.016). No statistically signifi-
cant association was seen between biophysical variables
or volume of contrast and development of CIN.
Conclusion: Ongoing inflammation doubles the likelihood
of development of CIN.
Advances in knowledge: This study highlights the impor-
tance of inflammation as a risk factor in the development
of CIN.
Intravascularly administered iodinated contrast media are
widely and liberally used in daily diagnostic radiological
investigations. The reason for this is that with regard to
volume administered, they are the safest intravascular phar-
maceutical agents. They are invaluable in discernment of
various pathological processes by radiologists through im-
proved tissue contrast, thus enabling prompt diagnoses and
management without performing invasive procedures. How-
ever, iodinated contrast media are not without side effects.
Of these, few have received as much attention as contrast-
induced nephropathy (CIN).1 CIN is the third commonest
cause of hospital-acquired renal injury, after hypotension
and use of nephrotoxic drugs.2
CIN is deﬁned as an elevation of serum creatinine (SCr)
of 25% above the baseline within 24–72 h of administration
of intravascular iodinated contrast media with no other
identiﬁable cause of renal insult.3,4 Because the majority of
patients do not have follow-up measurement of SCr, a large
number of patients who develop CIN pass unnoticed. Only
0.15–12.00% of patients who develop CIN require medical
intervention for the condition.5 This is a small subset of
patients considering studies in general populations have
revealed CIN incidence rates of 2–5%.6,7 However, even in
subclinical CIN, Levy et al8 demonstrated an excessive in-
crease in all-cause mortality in patients who developed
CIN, despite correction for other factors leading to
mortality.
CIN is an iatrogenic insult to the kidneys caused by in-
travascular administration of iodinated contrast media.
There is resultant kidney injury owing to multiple factors.9
One of the effects of intravascular iodinated contrast media
is transient vasodilatation followed by prolonged vaso-
constriction.10,11 An important hormone in this process is
adenosine, which causes vasodilatation by alpha-2 receptor
stimulation of the efferent arteriole and vasoconstriction
via alpha-1 receptor stimulation.12
Vasoconstriction is the predominant effect.13 While this
occurs in all patients who receive intravenous iodinated con-
trast, the incidence of CIN in the general population infers
that vasoconstriction alone is not a signiﬁcant factor in CIN.
The other two main pathways that are implicated in the
development of CIN are direct cellular toxicity and elevated
urinary viscosity with resultant crystal stone formation and
subsequent outﬂow obstruction.14
In an attempt to elucidate the cause of the elevated incidence of
CIN, it was noted that other factors along with vasoconstriction
may raise the risk of CIN.15
Low-income countries continue to grapple with a high infectious
disease burden, which means that the population has a higher
prevalence of inﬂammation than in high-income countries.16
It is well known that inﬂammatory mediators are thrombogenic.17
Interleukins (ILs) are released in both infectious and malignant
states, and IL-6 and IL-12 have been implicated in altering the
haemostatic mechanisms in primates and humans.18 IL-6 is known
to induce acute phase reactant production, notably C-reactive
protein (CRP).19,20 Severe inﬂammatory states such as sepsis have
been documented to increase the risk of developing CIN.17
Thus, if vasoconstriction is coupled with a prothrombotic
state—deﬁned as inﬂammation for the purposes of this study—
it is possible that this would reduce renal perfusion and cause
renal insult. Of note, the presence of acute inﬂammation has
not been assessed as an independent variable affecting the de-
velopment of CIN.21
CRP is a widely used biochemical marker for acute inﬂammation. It
rises above normal limits within 6h of onset of inﬂammation, peaks
in 48h and has a steady half-life that causes a rapid and predictable
fall once the inﬂammation has stopped.22 It thus presents a useful
tool in objectively stratifying study populations into patients with
and those without an active inﬂammatory process.
The majority of CIN studies are predominantly targeted at
high-risk groups. Few of the studies look at the overtly nor-
mal population, and none of the studies has an incidence of
CIN as high as 12–14% in the overtly normal population.23,24
An unpublished study by Mwanzi across three Kenyan hospitals
demonstrated a CIN incidence of 12–14% [Mwanzi, Aga Khan
University Hospital, 2009, personal communication], while
showing that human immunodeﬁciency virus infection does not
signiﬁcantly inﬂuence the development of CIN.25 The study did
not, however, address the reason for this disproportionately
higher incidence than the 2–5% found in other studies. This
study therefore sought to identify factors that may be more
predominant in the Kenyan setting that would signiﬁcantly raise
the incidence of CIN in the Kenyan populace.
METHODS AND MATERIALS
A prospective cohort study in a private, tertiary teaching and
referral hospital in Kenya enrolled a total of 423 consecutive
patients who were undergoing a contrast-enhanced CT (CECT),
gave informed, written consent and fulﬁlled the eligibility cri-
teria detailed below.
The sole intravenous contrast medium administered in this study
was non-ionic iso-osmolar 350mgml21 iodinated intravascular
contrast medium. Patients received 50, 100 and 150ml (17.5, 35.0
and 52.5 g) of iodinated intravenous contrast for CECT of the
head, CECT of the chest/abdomen and CT angiography studies,
respectively. These are the standard volumes of iodinated in-
travenous contrast administered for the above-named inves-
tigations in our department.
The patients were divided into two cohorts: the exposed group
who had a CRP level of .5mg dl21 and were thus considered to
have a current inﬂammatory state and the unexposed group who
had a CRP level of #5mg dl21 (normal value) and were thus
considered to not have a current inﬂammatory state.
Eligibility criteria
All patients above the age of 18 years presenting to the university
hospital who were to undergo a CECTscan within the study period
were offered the opportunity to participate in the study. Patients
were excluded from the study if any of the following features were
noted: known risk factors for CIN that include pre-existing im-
pairment of renal function (SCr.120mmol l21); patients who had
recently (,3 months) used nephrotoxic drugs (non-sterodial
anti-inﬂammatory drugs, select antibiotics and antineoplastic
agents); patients with a diagnosis of multiple myeloma; patients
who had recently (,72 h) received intravascularly administered
iodinated contrast media prior to the CECT; and patients in-
volved in other research studies who may have altered the
results of this study (e.g. drug trials).
Sample size determination
The required sample size of patients who were representative of
the population being studied to test the hypothesis that inﬂam-
mation is a risk factor in CIN was determined using Schlessel-
man’s formula for deriving prospective cohort sizes, which gave
an n value of 193 per cohort.26 A total of 386 patients were thus
required to give a power of 80% and assuming an incidence of
disease among the non-exposed of 3% (Figure 1).
Study procedures
CT technicians were trained to complete the questionnaires re-
lated to patient data and record the volumes of intravenous
contrast administered to each patient. At the time of the pro-
cedure, the CT technician on duty explained the study details to
the patient and obtained written consent. For patients who were
unable to give informed consent, the next of kin were given the
opportunity to do so in lieu of the patient. Where clariﬁcations
were required, the primary investigator was contacted and
provided the required information. Each patient was assigned a
study number and relevant information ﬁlled into the data col-
lection form. Blood samples were drawn prior to administration
of intravenous iodinated contrast by the primary investigator
or qualiﬁed personnel, except in cases where the patient already
had blood tests performed within 24 h. These samples were then
used to assess the CRP and SCr levels. The patient then un-
derwent the CECT as per standard protocol. Following com-
pletion of the CECT, the patient was informed of where and
when she/he would return for the second blood sample if they
were outpatients. For inpatients, routine blood tests were used
or, where this was not available, blood samples were speciﬁcally
drawn for the study. The second set of blood samples were
submitted to the laboratory for SCr measurement.
Data collection
Using data collection forms, each patient was assigned a unique
study number. Descriptive patient data (age, sex, weight and
height) were obtained from the patient at the time of the CECT
scan and recorded in the data collection tool. Laboratory data
were obtained from the patient records at the time of CECT scan
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and during the follow-up visit. Post SCr measurements were
obtained from the laboratory 24–72 h after the post CECT SCr
measurement was taken. Data entry was performed by the pri-
mary investigator and double checked for accuracy at the time of
completion of data collection.
Data management and analysis
Data were entered into Microsoft Excel® v. 2010 (Microsoft,
Redmond, WA) and analysed using Stata® software v. 12 for
Windows (StataCorp LP, College Station, TX).
Once all the data had been entered into the spread sheet, data
error identiﬁcation was performed via frequency distribution tables
to identify any out of range values. Where discrepancies arose (three
patients), the data entry forms were used to resolve the error.
A x2 test was used to assess for relative risk of developing CIN
given an ongoing inﬂammatory state.
Multiple logistic regression analysis was then performed to ex-
plore any independent determinants of outcome in the bio-
physical variables captured and volume of contrast administered
that led to the development of CIN. The results were expressed as
odds ratio (OR), with its respective 95% conﬁdence interval (CI).
RESULTS
423 patients were included in the study. Of these, 215 patients
had elevated CRP and 208 normal CRP values.
The mean age of the sample population was 50 years with the
youngest patients being 18 years of age and the eldest a 91-year-
old female patient (Figure 1).
209 (49%) of the patients were male and 214 (51%) female.
The incidence of CIN in this study was 9.92%. Of the patients
with inﬂammation, 29 (13.5%; CI, 8.90–18.07) developed CIN,
while 13 (6.25%; CI, 2.96–9.54) of those without inﬂammation
developed CIN (Table 1).
The multivariate regression analysis revealed that none of the
biophysical variables (age, sex or weight) or the volume of
contrast administered (50, 100 and 150ml converted by weight
for volume to 17.5, 35.0 and 52.5 g, respectively) had any statis-
tically signiﬁcant association with development of CIN (Table 2).
DISCUSSION
Iodinated contrast media are known to have two main classes of
adverse effects: idiosyncratic and physiochemotoxic.27
The idiosyncratic adverse effects are also known as anaphylactoid
reactions. They are not dose dependent and mimic anaphylactic
(allergic) reactions via enzyme induction causing release of va-
soactive substances, e.g. histamine and serotonin, and the sub-
sequent activation of the complement system.
The physiochemotoxic reactions are postulated to result from the
ability of iodinated contrast media to disrupt the body’s homoeo-
static mechanisms, most notably the circulatory system. These
reactions are largely owing to the physical and chemical effects of
the contrast molecules and are thus considered dose dependent.
CIN is a physiochemotoxic adverse reaction to intravascular
iodinated contrast that has varying deﬁnitions. The commonly
applied deﬁnition is an absolute increase in SCr of 25% above
the baseline within 24–48 h of intravascular iodinated contrast
media without any other identiﬁable cause of the renal injury.3,4
Although this deﬁnition is the most widely held, it is not with-
out controversies.28 SCr, for instance, can ﬂuctuate to levels
greater or lesser than 25% of a baseline reading without ad-
ministration of iodinated contrast media. Furthermore, intrinsic
renal damage can exist with “normal” SCr levels. Novel methods
of identifying renal parenchymal damage exist (serum cystatin
C), but these have not been validated in the assessment of CIN.29
Several studies have been performed that have established
major risk factors for development of CIN. These include pre-
existing renal injury, best identiﬁed by an elevated baseline SCr;
nephrotoxic drug use; dehydration; administration of iodinated
contrast media within 72h preceding repeat contrast media dose;
patients with multiple myeloma; and patients with sepsis.14
These risk factors are well established, and patients with one or
more of these factors are considered high risk for development
of CIN. Noting that patients with multiple myeloma and those
with sepsis were both in prothrombotic state, it was hypothe-
sized that the prothrombotic state contributed by the disease
was responsible for the increased risk of developing CIN. In-
ﬂammation is known to be a prothrombotic state. This study
thus sought to exclude patients with any identiﬁable risk factor
from our study and subsequently divide the patients into two
cohorts based on the presence or absence of ongoing inﬂam-
mation as discerned by the patient’s serum CRP level.
ILs are cytokines that are released by the immune system in both
infectious and malignant states. Of the ILs, IL-6 and IL-12 have
been implicated in altering the haemostatic mechanisms in
primates and humans.18 IL-6 is known to induce acute phase
reactant production, notably CRP in the human liver.19,20
In this study, the cohort of patients who had a normal CRP
measurement had an incidence of CIN of 6.25%, which is at the
Figure 1. Age of patients relative to the amount of C-reactive
protein (CRP).
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upper end of the values described in other normal population
studies of 2–5%. However, the patients who had elevated CRP
measurements were noted to have a CIN incidence of 13.5%,
giving a relative risk of 2.16.
Exploration of other biophysical variables and administration
of dose of contrast were not associated with development of
CIN. Interestingly, in our study, no association was found be-
tween age and development of CIN (OR, 1.01; CI, 0.99–1.03).
This is unlike other studies that have found extremes of age to
be an independent risk factor.21,30 Part of the reason for this
discrepancy may be owing to the relatively low numbers in this
study (423) vs the numbers used to identify age as a risk factor
(8357 for Mehran et al30). Furthermore, studies that have looked
at age as an independent variable tend to be in high-risk pop-
ulations, e.g. patients undergoing coronary intervention and thus
likely to receive higher doses of iodinated contrast.
There was no association between the patient’s weight, sex or
administered volume of contrast and the development of CIN.
Previous studies have not found any association between patient
weight and CIN. This is largely because the administered volume
of contrast is not directly proportional to the patient’s body weight,
but rather standardized for the type of diagnostic scan performed.
Cochran et al21 performed a study that sought to identify various
risk factors that had signiﬁcant association with development of
CIN. Although sex was found to have a signiﬁcant OR of 3.2,
multiple logistic regression analysis essentially ruled it out as an
independent variable, as it was strongly associated with other more
attributable risk factors. Other studies since then have only shown
weak associations of sex with development of CIN. Our study had
no association between patient’s sex and development of CIN.
The dose of contrast administered in this study had no as-
sociation with development of CIN. This is likely because the
amount of contrast being administered was relatively low
(17.5–52.5 g5 50–150ml) as opposed to interventional proce-
dures that have varying and typically higher doses of contrast
administered.31 McCullough et al32 also showed that the risk of
CIN is minimal in patients receiving ,100ml of contrast media.
The results of this study highlight a two-fold increased risk of
developing CIN in patients with inﬂammation in the selected
patient demographic.
Study limitations
The study was conducted in a private hospital setting where the
majority of the clientele either have medical insurance or can
afford to pay their healthcare costs in cash. This does not mirror
the economic capacity of the country—and therefore the health-
seeking behaviour—in which the study has been undertaken and
as such, may not be generalizable.
Secondly, select inﬂammatory states do not exhibit a rise in CRP,
e.g. scleroderma, polymyositis and dermatomyositis. As such,
CRP cannot be reliably used to assess for inﬂammation in
patients with these conditions. In such patients, use of cystatin
C as a biomarker of renal injury can be considered. However,
considering that these conditions are quite rare (e.g. scleroderma
incidence is 19 cases per 1,000,000 in the USA), they are unlikely
to have caused signiﬁcant bias.
Thirdly, the study did not categorize the various causes of el-
evation of CRP, which limits the ability to assess for the effects
of various inﬂammatory states, e.g. infection and malignancy
on the development of CIN. A larger study with stratiﬁcation
of causes of inﬂammation may further elucidate the relation-
ship between various inﬂammatory states and CIN.
CONCLUSION
This study demonstrated that the presence of inﬂammation in-
creases the likelihood of development of CIN. This is the probable
reason for the three-to-ﬁve fold increased incidence of CIN in the
Kenyan population as compared with the developed world.
Table 1. Incidence of contrast-induced nephropathy (CIN)
Descriptor CIN No CIN Total Incidence of CIN (%)
Inﬂammation 29 186 215 13.5
No inﬂammation 13 195 208 6.25
Total 42 381 423 9.92
Inflammation defined as an elevated C-reactive protein .5mgdl21.
Table 2. Biophysical and inflammatory variables associated with contrast-induced nephropathy (CIN)
CIN Odds ratio Significance (p) 95% confidence interval
Inﬂammation 2.368307 0.016 1.177981 4.761435
Weight (kg) 0.990807 0.406 0.969441 1.012643
Sex (ref: male) 1.008584 0.980 0.524649 1.938900
Age 1.012129 0.225 0.992625 1.032016
Volume of contrast (ref: 50ml)
100ml 1.341906 0.607 0.437445 4.116434
150ml 1.315318 0.660 0.388184 4.456814
BJR EA Kwasa et al
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RECOMMENDATIONS
From the results of this study, we recommend that in a pa-
tient with a known risk factor for CIN, assessment for de-
tection of those with inﬂammation by use of a reliable
biomarker (CRP in this study) can be used to generate a
risk–beneﬁt analysis prior to administration of iodinated
intravenous contrast.
Furthermore, a larger study involving patients in public hospi-
tals should be performed that would have results that are more
generalizable.
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